Acorda Resubmits New Drug Application for INBRIJA (CVT-301, levodopa inhalation powder)
Acorda Therapeutics announced the resubmission of its New Drug Application (NDA) for INBRIJA to the U.S. Food and Drug Administration (FDA). INBRIJA is an investigational treatment for…
Read More...
Read More...
